Doxycycline
- Generic Name
- Doxycycline
- Brand Names
- Acticlate, Adoxa, Apprilon, Atridox, Doryx, Doxy, Doxycin, Lymepak, Mondoxyne, Monodox, Morgidox, Okebo, Oracea, Periostat, Targadox, Vibramycin
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24N2O8
- CAS Number
- 564-25-0
- Unique Ingredient Identifier
- 334895S862
- Background
Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.
- Indication
Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria, including:
It is also used to treat infections caused by the following gram-negative microorganisms:
- Associated Conditions
- Acinetobacter Infections, Anthrax, Bacterial Infection caused by Enterobacter aerogenes, Bartonellosis, Brucellosis, Campylobacter Infection, Chancroid, Chlamydia Trachomatis Infection, Early Lyme Disease, Granuloma Inguinale, Infection Due to Escherichia Coli, Inhalational Anthrax, Klebsiella Infections, Lymphogranuloma Venereum, Malaria caused by Plasmodium falciparum, Nongonococcal urethritis, Plague caused by Yersinia pestis, Psittacosis, Rectal infection caused by Chlamydia Trachomatis, Relapsing fever caused by Borrelia recurrentis, Respiratory Tract Infection Bacterial, Rickettsial infectious disorders, Severe Acne, Sexually Transmitted Infections (STIs), Shigella Infection, Trachoma inclusion conjunctivitis, Tularemia, Vibrio Cholerae Infection, Acute Intestinal amebiasis, Susceptible Bacterial Infections, Uncomplicated endocervical infection, Uncomplicated urethral infection
Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria
- Conditions
- Arthritis, ReactiveReiter Disease
- Interventions
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2018-11-13
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 42
- Registration Number
- NCT00351273
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
🇨🇦University of Toronto, Toronto, Ontario, Canada
🇺🇸Louisiana State University, New Orleans, Louisiana, United States
Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic Filariasis
- Conditions
- Mp MicrofilaremiaMansonella Perstans Infection
- First Posted Date
- 2006-06-21
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 1500
- Registration Number
- NCT00340691
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), 9000 Rockville Pi, Bethesda, Maryland, United States
NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)
- Conditions
- Urethritis
- Interventions
- First Posted Date
- 2006-05-08
- Last Posted Date
- 2019-03-01
- Target Recruit Count
- 305
- Registration Number
- NCT00322465
- Locations
- 🇺🇸
Delgado Personal Health Center, New Orleans, Louisiana, United States
🇺🇸University of Alabama Hospital - Infectious Diseases, Birmingham, Alabama, United States
🇺🇸University of North Carolina School of Medicine - Center for Infectious Diseases, Chapel Hill, North Carolina, United States
Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting
- Conditions
- Cardiopulmonary BypassReperfusion InjuryCoronary Artery Bypass Grafting
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 56
- Registration Number
- NCT00246740
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms
- Conditions
- AneurysmsArteriovenous Malformations
- Interventions
- First Posted Date
- 2005-10-25
- Last Posted Date
- 2013-10-09
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 26
- Registration Number
- NCT00243893
- Locations
- 🇺🇸
University of California, San Francisco, California, United States
Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever
- Conditions
- Relapsing Fever, Tick-borneJarisch Herxheimer Reaction
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Medical Corps, Israel Defense Force
- Target Recruit Count
- 140
- Registration Number
- NCT00237016
- Locations
- 🇮🇱
Israel Defence Forces, Tel Hashomer, Israel
Randomized Controlled Trial of Doxycycline to Prevent Acquisition of Mycoplasma Pneumoniae in an Outbreak Setting
- Conditions
- Mycoplasma Pneumoniae
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2005-09-21
- Lead Sponsor
- Centers for Disease Control and Prevention
- Registration Number
- NCT00207584
Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens
- Conditions
- Abortion, InducedVomiting
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 40
- Registration Number
- NCT00177333
- Locations
- 🇺🇸
Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
Placebo Versus Antibiotics in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- Medical Center Alkmaar
- Target Recruit Count
- 258
- Registration Number
- NCT00170222
- Locations
- 🇳🇱
Medisch centrum Alkmaar, Alkmaar, Noord-holland, Netherlands
Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Sorlandet Hospital HF
- Target Recruit Count
- 120
- Registration Number
- NCT00138801
- Locations
- 🇳🇴
Sørlandet Sykehus HF, Kristiansand, Vest-Agder, Norway
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.